2 results
Approved WMOCompleted
Primary:To investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis, as measured by thetime to onset of confirmed disability progression over the treatment period, defined as an increase…
Approved WMORecruiting
The primary objective to demonstrate that in CNOpatients with pain 3-monthly treatment with pamidronate will result in significant decrease in maximum pain score (as measured with BPI) as compared to placebo.Secondary objectives:•…